Democratic Republic of the Congo
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 68 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 46 (22–53) 68 (33–78)
Mortality (HIV+TB only) 6.4 (0.17–24) 9.5 (0.25–35)
Prevalence  (includes HIV+TB) 370 (190–610) 549 (285–898)
Incidence  (includes HIV+TB) 220 (200–240) 326 (297–356)
Incidence (HIV+TB only) 16 (9.8–75) 24 (14–111)
Case detection, all forms (%) 51 (47–56)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.6 (0.01–5.5) 13 (0.2–28)
MDR-TB cases among notified pulmonary
TB cases
2 200 (9–4 700) 900 (14–2 000)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 71 526   3 981
Pulmonary, clinically diagnosed 13 887   1 943
Extrapulmonary 20 297   805
       
Total new and relapse 112 439    
Previously treated, excluding relapses 1 164    
Total cases notified 113 603    
Among 71 526 new cases:
3 086 (4%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 344 (<1%) 1 070 (14%) 1 426
Laboratory-confirmed RR-/MDR-TB cases     272
Patients started on MDR-TB treatment     147
TB/HIV 2013 Number (%)
TB patients with known HIV status 49 816 (44)
HIV-positive TB patients 6 984 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 866 (70)
HIV-positive TB patients on antiretroviral therapy (ART) 3 371 (48)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 88
Previously treated cases registered in 2012 74
HIV-positive TB cases, all types, registered in 2012 0
RR-/MDR-TB cases started on second-line treatment in 2011 59
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 0.1
Drug susceptibility testing (per 5 million population) <0.1
Sites performing Xpert MTB/RIF 26
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 66
% Funded domestically 3%
% Funded internationally 21%
% Unfunded 75%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-05 Data: www.who.int/tb/data